Cargando…

Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data

BACKGROUND: Neuropathy is a common chronic complication in type 2 diabetes mellitus (T2DM). Statin and metformin are commonly used medications in T2DM patients, and some studies showed statin- or metformin-induced neuropathy. AIM: To evaluate the incidence of neuropathy among patients with T2DM asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Hong Ki, Kim, Se Hee, Choi, Jong Han, Choi, Kyomin, Kim, Hae-Rim, Lee, Sang-Heon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638058/
https://www.ncbi.nlm.nih.gov/pubmed/34904090
http://dx.doi.org/10.12998/wjcc.v9.i33.10198
_version_ 1784608875298684928
author Min, Hong Ki
Kim, Se Hee
Choi, Jong Han
Choi, Kyomin
Kim, Hae-Rim
Lee, Sang-Heon
author_facet Min, Hong Ki
Kim, Se Hee
Choi, Jong Han
Choi, Kyomin
Kim, Hae-Rim
Lee, Sang-Heon
author_sort Min, Hong Ki
collection PubMed
description BACKGROUND: Neuropathy is a common chronic complication in type 2 diabetes mellitus (T2DM). Statin and metformin are commonly used medications in T2DM patients, and some studies showed statin- or metformin-induced neuropathy. AIM: To evaluate the incidence of neuropathy among patients with T2DM associated with statin and metformin therapies. METHODS: Korean Health Insurance Review and Assessment national patient sample data from 2016 and 2017 were used. Patients with T2DM and no complications were divided into statin/metformin/statin + metformin users and non-users. Neuropathy incidence was defined by International Statistical Classification of Diseases and Related Health Problems, 10(th) revision codes and concomitant prescriptions for anticonvulsants or antidepressants. Logistic regression analyses were conducted to examine the associations between statin/metformin/statin + metformin therapies and the incidence of neuropathy. Propensity score (PS) matching was performed on the basis of age, sex and comorbidities. RESULTS: Overall, 34964 and 35887 patients with T2DM and no complications were included in the Korean Health Insurance Review and Assessment national patient sample datasets from 2016 and 2017, respectively. Statin therapy was associated with increased risks of neuropathy in 2016 and 2017 [PS-matched odds ratio (OR) = 1.22, 95% confidence interval (CI): 1.08-1.38; PS-matched OR = 1.17, 95%CI: 1.03-1.33, respectively]. Metformin therapy was associated with reduced risks of neuropathy in 2016 and 2017 (PS-matched OR = 0.30, 95%CI: 0.21-0.42; PS-matched OR = 0.44, 95%CI: 0.32-0.60, respectively). Combined statin + metformin therapy was not significantly associated with neuropathy in 2016 or 2017 (PS-matched OR = 0.85, 95%CI: 0.61-1.19; PS-matched OR = 0.95, 95%CI: 0.66-1.38, respectively). CONCLUSION: Statin therapy was associated with enhanced risk of new-onset neuropathy in patients with T2DM, but metformin therapy showed the opposite association.
format Online
Article
Text
id pubmed-8638058
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-86380582021-12-12 Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data Min, Hong Ki Kim, Se Hee Choi, Jong Han Choi, Kyomin Kim, Hae-Rim Lee, Sang-Heon World J Clin Cases Observational Study BACKGROUND: Neuropathy is a common chronic complication in type 2 diabetes mellitus (T2DM). Statin and metformin are commonly used medications in T2DM patients, and some studies showed statin- or metformin-induced neuropathy. AIM: To evaluate the incidence of neuropathy among patients with T2DM associated with statin and metformin therapies. METHODS: Korean Health Insurance Review and Assessment national patient sample data from 2016 and 2017 were used. Patients with T2DM and no complications were divided into statin/metformin/statin + metformin users and non-users. Neuropathy incidence was defined by International Statistical Classification of Diseases and Related Health Problems, 10(th) revision codes and concomitant prescriptions for anticonvulsants or antidepressants. Logistic regression analyses were conducted to examine the associations between statin/metformin/statin + metformin therapies and the incidence of neuropathy. Propensity score (PS) matching was performed on the basis of age, sex and comorbidities. RESULTS: Overall, 34964 and 35887 patients with T2DM and no complications were included in the Korean Health Insurance Review and Assessment national patient sample datasets from 2016 and 2017, respectively. Statin therapy was associated with increased risks of neuropathy in 2016 and 2017 [PS-matched odds ratio (OR) = 1.22, 95% confidence interval (CI): 1.08-1.38; PS-matched OR = 1.17, 95%CI: 1.03-1.33, respectively]. Metformin therapy was associated with reduced risks of neuropathy in 2016 and 2017 (PS-matched OR = 0.30, 95%CI: 0.21-0.42; PS-matched OR = 0.44, 95%CI: 0.32-0.60, respectively). Combined statin + metformin therapy was not significantly associated with neuropathy in 2016 or 2017 (PS-matched OR = 0.85, 95%CI: 0.61-1.19; PS-matched OR = 0.95, 95%CI: 0.66-1.38, respectively). CONCLUSION: Statin therapy was associated with enhanced risk of new-onset neuropathy in patients with T2DM, but metformin therapy showed the opposite association. Baishideng Publishing Group Inc 2021-11-26 2021-11-26 /pmc/articles/PMC8638058/ /pubmed/34904090 http://dx.doi.org/10.12998/wjcc.v9.i33.10198 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Observational Study
Min, Hong Ki
Kim, Se Hee
Choi, Jong Han
Choi, Kyomin
Kim, Hae-Rim
Lee, Sang-Heon
Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data
title Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data
title_full Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data
title_fullStr Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data
title_full_unstemmed Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data
title_short Impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: Korean Health Insurance data
title_sort impacts of statin and metformin on neuropathy in patients with type 2 diabetes mellitus: korean health insurance data
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638058/
https://www.ncbi.nlm.nih.gov/pubmed/34904090
http://dx.doi.org/10.12998/wjcc.v9.i33.10198
work_keys_str_mv AT minhongki impactsofstatinandmetforminonneuropathyinpatientswithtype2diabetesmellituskoreanhealthinsurancedata
AT kimsehee impactsofstatinandmetforminonneuropathyinpatientswithtype2diabetesmellituskoreanhealthinsurancedata
AT choijonghan impactsofstatinandmetforminonneuropathyinpatientswithtype2diabetesmellituskoreanhealthinsurancedata
AT choikyomin impactsofstatinandmetforminonneuropathyinpatientswithtype2diabetesmellituskoreanhealthinsurancedata
AT kimhaerim impactsofstatinandmetforminonneuropathyinpatientswithtype2diabetesmellituskoreanhealthinsurancedata
AT leesangheon impactsofstatinandmetforminonneuropathyinpatientswithtype2diabetesmellituskoreanhealthinsurancedata